BIENNIAL REPORT OF EXAMINING AND LICENSING BOARDS

(M.S. - 1987 Supplement, Section 214.07)

BOARD: MINNESOTA BOARD OF PHARMACY

LOCATION: 2700 University Ave. W. #107, St. Paul, MN 55114

STATUTORY AUTHORITY: Minnesota Statute 151

REPORTING PERIOD: July 1, 1986 to June 30, 1988

SUBMITTED BY: David E. Holmstrom, Executive Director

DATE: October 1, 1988

Distribution:
1 copy to Secretary of Senate
1 copy to Clerk of the House
10 copies to Legislative Reference Library
1 copy to the Governor
1 copy to the Commissioner of the Department of Health

Clause a: GENERAL STATEMENT OF BOARD ACTIVITIES

The function of the Minnesota Board of Pharmacy is to protect the public from adulterated, misbranded, and illicit drugs and to provide the public reasonable assurance of professional competency in the practice of the pharmacy profession through the enforcement of the provisions of the Pharmacy Practice Act, the State Controlled Substances Act, and miscellaneous other acts. Such enforcement involves drug control through testing, licensing, inspecting, and investigating 4,352 pharmacists, 236 pharmacist-interns, 1,398 pharmacies, 219 drug wholesalers, 149 drug manufacturers and 67 drug researchers; through the providing of technical assistance, training and consultation to other health professionals; and through the development of rules and regulations governing storage, distribution, and recordkeeping by persons, institutions, and facilities.

This general function of the Board can essentially be broken down into eight different activities:

(1) Licensing of Pharmacists. Candidates for licensure as pharmacists are examined by Board members in a combination of five professional fields. In addition, a practical examination involving the compounding and dispensing of prescriptions is prepared and administered by the Board members.

Candidates for licensure by reciprocity are cleared through the National Association of Boards of Pharmacy for evidence of proper educational and experience credentials as well as for compliance with pharmacy laws. Only the state exam in pharmaceutical jurisprudence is required of candidates for licensure by reciprocity.

Twice yearly survey/inspections review compliance with: required professional staffing standards, internship training and practice, standards of drug storage and drug quality, minimum equipment, prepackaging activities, bulk compounding, compounding and dispensing, consultation under Medicare requirements, recordkeeping, labeling, security, and miscellaneous practice requirements. In the case of pharmacists in institutional practice, special emphasis is given to the overall drug distribution systems utilized and recognition is given to special compounding and dispensing practices unique to the institutional practice setting.

Beginning with the March 4, 1975 licensing renewal, all pharmacists currently licensed in Minnesota are required to show evidence of having obtained thirty hours of continuing pharmaceutical education every two years in order to maintain their license. Programs from various local, state, and national sponsors must be reviewed and approved for use in meeting the continuing educational requirement. Biennially reports of continuing education attendance and participation must be reviewed and recorded prior to approving the annual registration for pharmacists.

(2) Pharmacy Licensure. Licenses are issued for each pharmacy, community and institutional, in the name of a designated pharmacist-in-charge who must demonstrate that required professional staffing, access, space, security, and equipment standards are met. Each pharmacy is inspected at least annually for compliance with applicable laws and regulations.

(3) Licensure of Drug Wholesalers. All firms handling drugs on a wholesale basis in Minnesota or who are doing business in Minnesota are required to be licensed by the Board. These firms must demonstrate adequate security, temperature and humidity control, sanitation, recordkeeping, and distribution practices at the time of licensing.

Inspection of drug wholesalers are accomplished approximately annually. Attention is given to storage and security capabilities of the firm. Distribution patterns are carefully reviewed to ensure that drugs are sold only to persons legally permitted to possess them. Sanitation is carefully surveyed and environmental control is reviewed.

(4) Licensure of Drug Manufacturers. All firms engaging in the manufacturing, repackaging, or relabeling of drugs are required to be licensed by the Board. At the time of licensure, all firms are required to demonstrate qualification of responsible personnel, records of compliance with drug laws, and equipment and procedures necessary to comply with the good manufacturing procedures of the Food and Drug Administration.

Comprehensive inspections of in-state drug manufacturers are accomplished by the Board's staff on approximately an annual basis. Special attention is given to: source and quality of raw materials; adequacy of building facilities, sanitation, and equipment; design and utilization of master formulas and batch records; manufacturing processes and techniques; in-process security and controls for controlled substances; content and security of labels; packaging control procedures and records; laboratory controls and records; and patterns of distribution of the manufactured product.

(5) Registration of Pharmacist-Interns. Pharmacy students may register as a pharmacist-intern at the end of the third year of the standard five or six year college of pharmacy curricula. Objectives of the internship training program and instructions for performance of pharmacy intern functions and reporting of practical learning experiences are furnished to the interns. Quarterly reports are required of each pharmacy student engaged in the pharmacist-intern practice. Experience as a pharmacist-intern may be obtained in the last two years of the college curriculum and must be commensurate with the interns educational level. Quality of experience is monitored and disciplinary actions taken against pharmacist preceptors or interns who violate internship regulations.

Interns are required to take a competency based pre and post-test series of examinations prepared by the Board's staff during and at the completion of their internship experience. The "pre-test" examinations are analyzed to show the intern the competency areas in which he should strive to gain more experience.

(6) Controlled Substances Regulation. All controlled substances (formerly designated as narcotics or stimulants and depressants) are catagorized in M.S. 152 into "Schedules" based on abuse potential. Rescheduling of controlled substances or addition of such substances to one of the existing schedules is accomplished by Board Rule 6800.4200 through 6800.4250. The Board may consult an advisory council on controlled substances on rescheduling proposals and in the consideration of control of newly discovered substances with abuse potential. The Board prescribes recordkeeping requirements for persons authorized to possess controlled substances and will, together with its advisory council, report to the legislature concerning implementation of the Controlled Substances Act and possible amendments to it. This general activity will be perpetual as long as the need for control of such substances with abuse potential exists.

Federal and state drug control activities are coordinated by the Board in a formal agreement with the Federal Drug Enforcement Administration and State Bureau of Criminal Apprehension. This coordination ensures DEA and BCA involvement in "street type" enforcement work and Board of Pharmacy involvement in cases involving illicit drug distribution from any of the various licensed health professionals.

(7) Miscellaneous Drug Control Activities. Investigation of registrants and non-registrants alike for compliance with miscellaneous laws relating to drugs and the provision of special investigative services to other state agencies in the health care and law enforcement areas are involved in Board activities. Other areas of Board activities include:

On-site inspection of distressed drugs which have been subjected to fire, flood, etc., is accomplished by Board staff. Drugs are inspected for evidence of misbranding or adulteration and are embargoed and destroyed if evidence of adulteration or misbranding is present. Similar inspections of distressed drugs which are imported into the state by various salvage companies are performed.

Careless distribution of drug samples is investigated to ensure that all drugs within the state will be distributed legally and safely.

Cases of illegal distribution or possession of hypodermic syringes and needles are investigated.

Compliance with the State Toxic Glue Law is achieved in part by the monitoring of compliance by our licensees.

Special investigations are performed in cooperation with or after requests of other state agencies such as the Department of Health, the Board of Medical Examiners, the Board of Dental Examiners, the Board of Nursing, and the Attorney General.

(8) Registration of Drug Researchers. All individuals seeking to utilize controlled substance drugs in research activities are required to obtain both a state and a federal registration in order to purchase, possess and use these drugs. State registration is carried out through the Board of Pharmacy office and information on these registrants is shared with the federal Drug Enforcement Administration.

All of these activities remained essentially unchanged in both fiscal years '87 and '88.

Clause B: TOTAL NUMBER MEETINGS HELD FY 87 IS 9 MEETINGS, FY 88 IS 9 MEETINGS, FY 85 & 86 IS 18 MEETINGS

BOARD MEMBER'S NAME	TYPE	FY 87	FY 88	FY 87 & 88
Doris Calhoun	Board Meeting	47	53	100
	Committees	4	2	6
	Other Meetings	37	23	60
	Disciplinaries	5	5	10
	Examination	20	41	61
	Grading	5	8	13
Henry Capiz	Board Meeting	65	70	135
	Committees	5	0	5
	Other Meetings	63	4	67
	Disciplinaries	13	20	33
	Examination	31	28	59
	Grading	21	8	29
Pat DeLaPointe	Board Meeting	57	42	99
	Committees	5	2	7
	Other Meetings	47	22	69
	Disciplinaries	13	3	16
	Examination	42	29	71
	Grading	6	8	14
Mike Hart	Board Meeting	28	0	28
	Committees	14	0	14
	Other Meetings	0	0	0
	Disciplinaries	0	0	0
	Examination	7	0	7
	Grading	0	0	0
Patricia Lind	Board Meeting	50	53	103
	Committees	10	7	17
	Other Meetings	44	21	65
	Disciplinaries	7	6	13
	Examination	35	40	75
	Grading	7	8	15
George Medich	Board Meeting	55	49	104
	Committees	0	0	0
	Other Meetings	54	23	77
	Disciplinaries	0	5	5
	Examination	34	43	77
	Grading	4	8	12

Ove Wangensteen	Board Meeting	42	49	91
	Committees	3	0	3
	Other Meetings	53	21	74
	Disciplinaries	3	2	5
	Examination	30	40	70
	Grading	3	8	7
Joseph Zastera, Jr.	Board Meeting	62	55	117
	Committees	3	3	6
	Other Meetings	44	23	67
	Disciplinaries	18	10	28
	Examination	44	44	88
	Grading	8	8	16

Volume II: THE BUDGET AND DISBURSEMENTS OF BOARD ITEMS

	FY 87	FY 88	FY 87 & 88
Total State Appropriations	372,304	385,635	757,939
Total Non-Dedicated Fee Receipts	421,100	429,200	850,300
Total Disbursements	372,011	370,000 (Est)	742,011

Clause d: LIST OF BOARD MEMBERS WHO SERVED DURING FY 87 AND FY 88

For easy reference please give:

a) Number of Board members required by statute: 7

b) The statutory length of term: 4 years

NAME AND ADDRESS	OCCUPATION	BEGIN AND END DATE OF APPOINTMENT AND EACH REAPPOINTMENT
Michael E. Hart, Jr. Forest Lake, MN	Pharmacist	3/9/83 - 1/87
Patricia Lind Eden Prairie, MN	Sales Person for office supplies	3/9/83 - 1/87
Joseph F. Zastera Two Harbors, MN	Pharmacist	1/3/84 - 1/88
Patricia DeLaPointe Hibbing, MN	Pharmacist	1/3/84 - 1/88
George Medich Cloquet, MN	Pharmacist	1/3/84 - 1/89
Ove M. Wangensteen Olivia, MN	Retired	1/6/86 - 1/90
Henry T. Capiz St. Paul, MN	Pharmacist	1/6/86 - 1/90
Patricia Lind Eden Prairie, MN	Sales Person for office supplies	1/87 - 1/91
Doris A. Calhoun St. Paul, MN	Pharmacist	1/87 - 1/91
Joseph F. Zastera, Jr. Two Harbors, MN	Pharmacist	1/88 - 1/92
Patricia DeLaPointe Hibbing, MN	Pharmacist	1/88 - 1/92

Clause e: LIST BOARD EMPLOYEES WHO WERE EMPLOYED DURING FY 87 AND/OR FY 88

NAME	JOB CLASSIFICATION/ TITLE AND CLASS	CLASS CODE	FT	PT	DATES OF SERVICE
David Holmstrom	Executive Director	OUNC	X		12/29/71 to Present
Alice Hummer	Office Service Supervisor II	0293	X		12/27/65 to Present
Merlin Beise	Pharmacy Surveyor	1347	X		6/18/73 to 10/16/86
Allen Conger	Pharmacy Surveyor	1347	X		5/13/74 to 10/9/87
Patricia Eggers	Clerk Typist IV	0666	X		6/16/77 to Present
Lloyd Pekas	Pharmacy Surveyor	1347	X		11/7/77 to Present
Gloria Passer	Clerk Typist II	0980	X		6/4/84 to 9/25/87
Ronald Rogers	Pharmacy Surveyor	1347	X		12/29/86 to Present
Judy Sande	Clerk Typist II	0980	X		10/15/87 to Present
Patricia Bellino	Pharmacy Surveyor	1347	X		3/16/88 to Present

Clause f: **BRIEF SUMMARY OF BOARD RULES PROPOSED OR ADOPTED DURING THIS REPORTING PERIOD, FY 87 AND FY 88. GIVE APPROPRIATE CITATIONS TO THE STATE REGISTER AND PUBLISHED RULES FOR THOSE ADOPTED.**

On August 29, 1987 the Minnesota Board of Pharmacy adopted the following changes in its rules.

6800.0400 ANNUAL LICENSE RENEWAL DATE AND FEES.

Each pharmacy license shall expire on June 30 of each year and shall be renewed annually by filing an application for license renewal, on or before June 1 of each year, together with a fee of $100. Renewal applications received on or after July 1 are subject to a late filing fee of $50 in addition to the renewal fee.

6800.1250 APPLICATIONS FOR LICENSURE.

Subpart 1. Submitting. Applicants for licensure by examination shall submit a completed application for examination including affidavits of internship, a copy of applicant's birth certificate, and a recent photograph. All applicants shall show evidence of graduation with a bachelor of science degree or doctor of pharmacy degree, as the first professional undergraduate degree in pharmacy, from a college of pharmacy or a department of pharmacy of a university approved by the board and meeting at least the minimum standards set by the `American Council on Pharmaceutical Education in the current edition of its accreditation manual. Such evidence shall be shown by submitting a final transcript showing the date on which degree was conferred. The above-listed documents together with a check for $125 must be submitted to the board at least 30 days prior to the examination.

Subpart 2. Retaking exam. Any applicant who has failed to pass the examination required by Minnesota Statutes, section 151.06, 151.07, 151.10, or 151.12, may retake such examination within the next ensuing 14 months, provided that no applicant who has failed in three examinations shall be permitted to take a further examination, except upon petition setting forth facts acceptable to the board. The applicant shall, at least 30 days before an examination, notify the board in writing of his or her intentions to retake the examination, certifying that information furnished on the original application remains true and correct, or reporting any changes therein, including additional education and experience, and shall submit a fee of $125 payable to the Minnesota Board of Pharmacy. The board reserves the right to request a full and complete application.

Subp. 3. [Unchanged.]

On December 30, 1986 the Minnesota Board of Pharmacy adopted the following changes in its rules.

6800.4210 SCHEDULE I CONTROLLED SUBSTANCES.

Schedule I shall consist of the drugs and other substances, by whatever official name, common or unusual name, chemical name, or brand name designated, listed in this part.

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers (whether optical, positional, or geometric), esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

(1) to (30) [Unchanged.]
(31) MPPP; 1-Methyl-4-Phenyl-4-Propionoxypiperidine
(32) Methyl substituted isomers of Fentanyl;
  (a) 3-Methylfentanyl; N-[3-Methyl-a-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide
  (b)Acetyl-alpha-methylfentanyl; N-1[1-Methyl-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide
  (c) Alpha-methylthiofentanyl; N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
  (d) Benzulfentanyl; N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
  (e) Beta-hydroxyfentanyl; N-[1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]
  (f) Beta-hydroxy-3-Methylfentanyl; N-[Methyl-1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide
  (g) 3-Methylthiofentanyl; N-[3-Methyl-1-(2-(-thienyl)ethyl)-4-piperidyl]-N-phenylpropananmide
  (h) Thenylfentanyl; N-[1-(2-thienyl)Methyl-4-piperidyl]-N-phenylpropanamide
  (i) Thiofentanyl; N-[1-(2-(2-thienyl)ethyl)-4-piperidyl]-N-phenylpropanamide
  (j) N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamide (Para-fluorofentanyl), its optical isomers, salts and salts of isomers
(33) Morpheridine;
(34) Noracymethadol;
(35) Norlevorphanol;
(36) Normethadone;
(37) Norpipanone;
(38) PEPAP; 1-(2-Phenylethyl)-4-Phenyl-4-Acetyloxypiperidine
(39) Phenadoxone;
(40) Phenampromide;
(41) Phenomorphan;
(42) Phenoperidine;
(43) Piritramide;
(44) Proheptazine;
(45) Properidine;
(46) Propiram;
(47) Racemoramide;

(48) Tilidine; and
(49) Trimeperidine.

B. [Unchanged.]

C. Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers (whether optical, positional, or geometric), and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1) to (21) [Unchanged.]	
(22) Tetrahydrocannabinols Synthetic equivalents of the substances contained in the plant, or in the resinous extractives of cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activities such as the following: 1 cis or trans tetrahydro-cannabinol, and their optical isomers, excluding dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration. 6 cis or trans tetrahydro-cannabinol, and their optical isomers; 3,4 cis or trans tetra-hydrocannabinol, and its optical isomers (Since nomenclature of these substances is not internationally standarized, compounds of these structures, regardless of numerical designation of atomic positions covered.)	THC
(23) to (25) [Unchanged.]	

D. to F. [Unchanged.]

6800.4220 SCHEDULE II CONTROLLED SUBSTANCES.

The following items are listed in schedule II:

A. [Unchanged.]

B. Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including the following:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(a) to (i) [Unchanged.]	
(j) Hydrocodone	Dihydrocodeinone,
(k) to (p) [Unchanged.]	

(2) to (3) [Unchanged.]

(4) Coca leaves and any salt, cocaine compound, derivative, or preparation of coca leaves and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.

(5) [Unchanged.]

C. to F. [Unchanged.]

G. Hallucinogenic substances.

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product.

6800.4240 SCHEDULE IV CONTROLLED SUBSTANCES.

The following items are listed in schedule IV:

A. and B. [Unchanged.]

C. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1) to (32) [Unchanged.]	
(33) Midazolam	
(34) Nimetazepam	
(35) Nitrazepam	
(36) Nordiazepam	
(37) Oxazepam	Serax
(38) Oxazolam	
(39) Paraledhyde	Paral
(40) Petrichloral	Periclor
(41) Phenobarbital	Luminal, Phenobarbitone, Eskabarb
(42) Pinazepam	
(43) Prazepam	Centrax
(44) Quazepam	
(45) Temazepam	Restoril
(46) Tetrazepam	
(47) Triazolam	Halcion

D. to F. [Unchanged.]

6800.4250 SCHEDULE V CONTROLLED SUBSTANCES.

The following items are listed in schedule V:

A. [Unchanged.]

B. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs and their salts, as set forth below:

(1) Buprenorphine

C. Narcotic drugs containing nonnarcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as follows, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:

Statutory Names	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1) to (3) [Unchanged.]	
(4) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.	Parapectolin, Donnagel P.G.
(5) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per disage unit.	

On May 4, 1988 the Minnesota Board of Pharmacy adopted the following changes in its rules:

6800.1250 APPLICATIONS FOR LICENSURE.

Subpart 1. Submitting. Applicants for licensure by examination shall submit a completed application for examination including affidavits of internship, a copy of applicant's birth certificate, and a recent photograph. All applicants shall show evidence of graduation with a bachelor of science degree or doctor of pharmacy degree, as the first professional undergraduate degree in pharmacy, from a college of pharmacy or a department of pharmacy of a university approved by the board and meeting at least the minimum standards set by the American Council on Pharmaceutical Education in the current edition of its accreditation manual. The evidence shall be shown by submitting an official final transcript showing the date on which degree was conferred. The above-listed documents together with a check for $200 must be submitted to the board at least 45 days prior to the examination. An applicant who is a graduate of a school or college of pharmacy located outside the United States, which has not been recognized and approved by the board, but who is otherwise qualified to apply for a license to practice pharmacy in this state, is considered to have satisfied the requirements of graduation if the applicant verifies to the board the applicant's academic record and the applicant's graduation. Before taking the licensing examination, a foreign graduate applicant shall pass the Foreign Pharmacy Graduate Equivalency Examination, which is recognized and approved by

the board, given by the Foreign Pharmacy Graduate Examination Commission and demonstrate proficiency in the English language by passing the Test of English as a Foreign Language, which is recognized and approved by the board, given by the Educational Testing Service as a prerequisite to taking the licensure examination.

Subp. 2. Retaking exam. Any applicant who has failed to pass the examination required by the Minnesota Statutes, section 151.06, 151.07, 151.10, or 151.12, may retake the examination within the next ensuing 14 months, provided that no applicant who has failed in three examinations shall be permitted to take a further examination, except upon petition setting forth facts acceptable to the board. The applicant shall, at least 45 days begore an examination, notify the board in writing of the intention to retake the examination, certifying that information furnished on the original application remains true and correct, or reporting any changes therein, including additional education and experience, and shall submit a fee of $200 payable to the Minnesota Board of Pharmacy. The board reserves the right to request a full and complete application.

Subp. 3. [Unchanged.]

6800.1600 CONTINUING EDUCATION ADVISORY TASK FORCE.

The continuing education advisory task force shall consist of not more than ten members. Three members of the advisory task force shall be pharmacists designated by the Minnesota State Pharmaceutical Association, three members shall be pharmacists designated by the Minnesota Society of Hospital Pharmacists, two members shall be pharmacists designated by the College of Pharmacy of the University of Minnesota, and two members shall be designated by the board. The continuing education advisory task force shall meet at least quarterly and shall annually elect a chair and vice-chair from its membership. The executive director of the board of pharmacy shall act as secretary to the task force.

6800.4210 SCHEDULE I CONTROLLED SUBSTANCES.

Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this part.

A. Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers (whether optical, positional, or geometric), esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is possible within the specific chemical designation:

(1) Acetylmethadol;
(2) Allylprodine;
(4) to (31) [Renumbered as (3) to (30)]
(31) Methyl substituted isomers of Fentanyl;
(a) to (i) [Unchanged.]
(j) para-fluorofentanyl; N-[1-(20phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamide, its optical isomers, salts and salts of isomers;
(33) to (49) [Renumbered as (32) to (48)]

B. to F. [Unchanged.]

6800.4220 SCHEDULE II CONTROLLED SUBSTANCES.

The following items are listed in schedule II:

A. and B. [Unchanged.]

C. Opiates. Unless specifically excepted or unless listed in another schedule any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1) Alfentanil	Alfenta
(1) to (24) [Renumbered as (2) to (25)]	

D. [Unchanged.]

E. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

Statutory Name	Some examples of common names, trade names, or names of products which contain a controlled substance.
(1) Amobarbital	Amytal
(2) Pentobarbital	Nembutal, Tuinal

(3) Phencyclidine — Sernyl, Sernylar
(4) Secobarbital — Seconal

F. [Unchanged.]

G. Hallucinogenic substances.

(1) [Unchanged.]

(2) Nabilone [another name for Nabilone: (+)-trans-3-(1,1-dimethylheptyl)-6,61,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo [b,d] pyran-9-one].

Clause g: **LIST THE NUMBER OF PERSON HAVING EACH TYPE OF LICENSE AND REGISTRATION ISSUED BY THE BOARD AS OF JUNE 30, 1988 (IN THE YEAR OF THE REPORT)**

TYPE OF LICENSE/REGISTRATION	TOTAL NUMBER IN EFFECT
Pharmacist	4,352
Pharmacy	1,398
Drug Wholesaler	219
Drug Manufacturer	149
Drug Researcher	67
Pharmacist-Intern	236

Clause h: ADMINISTRATION OF EXAMINATIONS BY BOARD

LOCATION	TYPES OF LICENSE/REGISTRATION	DATES	TYPE OF EXAM
MN Dept. of Health	Pharmacist/Reciprocity	9/23/86	Written/Oral
MN Dept. of Health	Pharmacist/Reciprocity	1/27/87	Written/Oral
Radisson University	Pharmacist/Examination	1/27/87	Written
Radisson University UofM College of Phcy.	Pharmacist/Examination	1/28/87	Written Practical
MN Dept. of Health	Pharmacist/Reciprocity	4/15/87	Written/Oral
MN Dept. of Health	Pharmacist/Reciprocity	6/23/87	Written/Oral
U of M	Pharmacist/Examination	6/23/87	Written
U of M UofM College of Phcy.	Pharmacist/Examination	6/24/87	Written Practical
MN Dept. of Health	Pharmacist/Reciprocity	10/20/87	Written/Oral
MN Dept. of Health	Pharmacist/Reciprocity	1/26/88	Written/Oral
Radisson University	Pharmacist/Examination	1/26/88	Written
Radisson University UofM College of Phcy.	Pharmacist/Examination	1/27/88	Written Practical
MN Dept. of Health	Pharmacist/Reciprocity	4/12/88	Written/Oral
MN Dept. of Health	Pharmacist/Reciprocity	6/28/88	Written/Oral
U of M	Pharmacist/Examination	6/28/88	Written
U of M UofM College of Phcy.	Pharmacist/Examination	6/28/88	Written Practical

Clauses i, j, k: MINNESOTA RESIDENTS BY TYPE OF LICENSE/REGISTRATION

Type of License/Registration: Pharmacist

FY 87

Age Group	Male	Female	Total
18 - 25	17 Passed	21 Passed	38 Passed
	2 Failed	3 Failed	5 Failed
26 - 34	15 Passed	6 Passed	21 Passed
	10 Failed	1 Failed	11 Failed
35 - 59	2 Passed	2 Passed	4 Passed
	0 Failed	0 Failed	0 Failed

FY 88

Age Gruop	Male	Female	Total
18 - 25	15 Passed	32 Passed	47 Passed
	1 Failed	3 Failed	4 Failed
26 - 34	13 Passed	17 Passed	30 Passed
	5 Failed	3 Failed	8 Failed
35 - 59	1 Passed	2 Passed	3 Passed
	3 Failed	2 Failed	5 Failed

FY 87 & 88

Age Group	Male	Female	Total
18 - 25	32 Passed	53 Passed	85 Passed
	3 Failed	6 Failed	9 Failed
26 - 34	28 Passed	23 Passed	51 Passed
	15 Failed	4 Failed	19 Failed
35 - 59	3 Passed	4 Passed	7 Passed
	3 Failed	2 Failed	5 Failed

Clauses i, j, k: NON-MINNESOTA RESIDENTS BY TYPE OF LICENSE/REGISTRATION

Type of License/Registration: Pharmacist

FY 87

Age Group	Male	Female	Total
18 - 25	8 Passed	18 Passed	26 Passed
	3 Failed	3 Failed	6 Failed
26 - 34	31 Passed	28 Passed	59 Passed
	7 Failed	4 Failed	11 Failed
35 - 59	8 Passed	8 Passed	16 Passed
	5 Failed	0 Failed	5 Failed

FY 88

Age Group	Male	Female	Total
18 - 25	11 Passed	20 Passed	31 Passed
	2 Failed	5 Failed	7 Failed
26 - 34	29 Passed	23 Passed	52 Passed
	5 Failed	3 Failed	8 Failed
35 - 59	21 Passed	6 Passed	27 Passed
	8 Failed	4 Failed	12 Failed
60 - 65	2 Passed	0 Passed	2 Passed
	0 Failed	0 Failed	0 Failed

FY 87 & 88

Age Group	Male	Female	Total
18 - 25	19 Passed	38 Passed	57 Passed
	5 Failed	8 Failed	13 Failed
26 - 34	60 Passed	51 Passed	111 Passed
	12 Failed	7 Failed	19 Failed
35 - 59	29 Passed	14 Passed	43 Passed
	13 Failed	4 Failed	17 Failed
60 - 65	2 Passed	0 Passed	2 Passed
	0 Failed	0 Failed	0 Failed

Total number of non-residents by state

FY 87:

	MALE		FEMALE		TOTAL	
STATE	PASSED	FAILED	PASSED	FAILED	PASSED	FAILED
AZ	1	0	1	0	2	0
CA	0	0	1	0	1	0
CO	1	0	3	0	4	0
IL	3	1	4	1	7	2
IA	6	0	6	1	12	1
KY	0	0	2	0	2	0
LA	0	1	0	0	0	1
MD	1	3	0	1	1	4
MA	0	0	1	0	1	0
MI	0	0	2	1	2	1
MO	0	1	1	0	1	1
MT	0	0	1	0	1	0
NE	0	0	3	1	3	1
NJ	2	0	0	0	0	0
NY	0	0	1	0	1	0
ND	15	5	17	1	32	6
OH	2	0	1	0	3	0
PA	1	0	0	0	1	0
SC	0	0	1	0	1	0
SD	3	1	1	0	4	1
TX	4	2	1	0	5	2
VA	1	0	0	0	1	0
WA	0	0	1	0	1	0
WV	1	0	0	0	1	0
WI	6	1	6	1	12	2

FY 88:

STATE	MALE PASSED	MALE FAILED	FEMALE PASSED	FEMALE FAILED	TOTAL PASSED	TOTAL FAILED
AZ	2	0	0	2	2	2
CA	0	0	1	1	1	1
CO	1	0	0	0	1	0
CT	1	0	0	0	1	0
IL	6	1	4	1	10	2
IN	0	0	2	0	2	0
IA	11	5	3	1	14	6
KY	1	0	0	0	1	0
LA	1	0	0	1	1	1
MD	1	0	0	0	1	0
MI	1	0	2	1	3	1
MO	1	0	1	0	2	0
MT	2	0	2	0	4	0
NE	1	2	0	0	1	2
NV	3	0	0	0	3	0
NY	0	0	2	1	2	1
NC	0	0	1	0	1	0
ND	14	4	15	0	29	4
OH	1	0	0	1	1	1
PA	0	1	2	1	2	2
SD	1	1	1	1	2	2
TN	2	0	0	0	2	0
TX	4	0	5	0	9	0
VA	1	0	1	0	2	0
WV	2	0	0	0	2	0
WI	5	1	6	1	11	2
WY	1	0	1	0	2	0

FY 87 & 88:

STATE	MALE PASSED	MALE FAILED	FEMALE PASSED	FEMALE FAILED	TOTAL PASSED	TOTAL FAILED
AZ	3	0	1	2	4	2
CA	0	0	2	1	2	1
CO	2	0	3	0	5	0
CT	1	0	0	0	1	0
IL	9	2	8	2	17	4
IN	0	0	2	0	2	0
IA	17	5	9	2	26	7
KY	1	0	2	0	3	0
LA	1	1	0	1	1	2
MD	2	3	0	1	2	4
MA	0	0	1	0	1	0
MI	1	0	4	2	5	2
MO	1	1	2	0	3	1
MT	2	0	3	0	5	0
NE	1	2	3	1	4	3
NV	3	0	0	0	3	0
NJ	2	0	0	0	2	0
NY	0	0	3	1	3	1
NC	0	0	1	0	1	0
ND	29	9	32	1	61	10
OH	3	0	1	1	4	1
PA	1	1	2	1	3	2
SC	0	0	1	0	1	0
SD	4	2	2	1	6	3
TN	2	0	0	0	2	0
TX	8	2	6	0	14	2
VA	2	0	1	0	3	0
WA	0	0	1	0	1	0
WV	3	0	0	0	3	0
WI	11	2	12	2	23	4
WY	1	0	1	0	2	0

Clause 1: **THE NUMBER OF PERSONS NOT TAKING EXAMINATIONS WHO WERE LICENSED OR REGISTERED BY THE BOARD OR WHO WERE DENIED LICENSING OR REGISTRATION WITH THE REASONS FOR THE LICENSING OR REGISTRATION OR DENIAL THEREOF.**

Total number of persons not taking exams and granted licenses or registration:

FY 87 = None
FY 88 = None
FY 87 & 88 = None

Total number of persons not taking exams and denied licenses or registration:

FY 87 = None
FY 88 = None
FY 87 & 88 = None

Clause m: **PERSONS PREVIOUSLY LICENSED OR REGISTERED BY THE BOARD WHOSE LICENSES OR REGISTRATIONS WERE REVOKED, SUSPENDED OR OTHERWISE ALTERED IN STATUS, WITH BRIEF STATEMENTS OF THE REASONS FOR THE REVOCATION, SUSPENSION OR ALTERATION.**

	FY 87	FY 88	FY 87 & 88
TOTAL number of revocations	129	52	181
TOTAL number of suspensions	12	13	25
TOTAL number of other status changes	26	29	55

Type of license or registration: All cases involved pharmacists

TYPE OF STATUS CHANGE			
REVOKED	SUSPENDED	OTHER (SPECIFY)	REASON FOR CHANGE
181			Non-payment of Fees
	2		Unprofessional Conduct
	1		Chemical Dependency/ Unprofessional Conduct
	2		Violation of Probation
	1		Practicing without a License
	9		Chemical Dependency
	1		Drug Diversion/ Unprofessional Conduct
	1		Welfare Fraud
	1 Voluntary Surrender of License		Controlled Substance Drug Diversion
	1 Voluntary Surrender of License		Chemical Dependency
		3 Suspension-Stayed	Chemical Dependency
		7 Suspension-Stayed	Unprofessional Conduct

1 Subject to Cease and Desist Order	Unprofessional Conduct
8 Warning Letters	Unprofessional Conduct
1 Probation	Chemical Dependency
1 Denial of Previous Intern Hours	Examination Fraud/ Unprofessional Conduct
1 Letter of Reprimand	Drug Diversion
1 Warning Letter	Incompetence
1 Warning Letter	Theft
2 Letter of Reprimand	Unprofessional Conduct
1 Agreement Letter	Chemical Dependency
1 Probation	Welfare Fraud
2 Letter of Reprimand	Incompetency
7 Probation	Unprofessional Conduct
7 Off Suspension	Chemical Dependency
1 Off Probation	Violation of Probation
1 Off Suspension	Violation of Probation
5 Off Probation	Chemical Dependency
1 Off Probation	Unprofessional Conduct
2 Off Suspension	Unprofessional Conduct
1 Off Suspension	Chemical Dependency/ Unprofessional Conduct
1 Off Suspension	Practicing Without a License
1 Off Suspension	Welfare Fraud
2 Off Probation	Welfare Fraud
2 Off Probation	Poor Practice

Clause n: LIST THE NUMBER OF COMPLAINTS AND OTHER COMMUNICATIONS RECEIVED BY THE EXECUTIVE DIRECTOR, EACH BOARD MEMBER, EMPLOYEE OR OTHER PERSON PERFORMING SERVICES FOR THE BOARD

That allege or imply a violation of a statute or rule which the Board is empowered to enforce. These totals include cases referred to the attorney general's staff who are assigned to assist your board.

	FY 87	FY 88
Written	43	49
Oral	24	20

Which are forwarded to other agencies as required by M.S. 214.10.

	FY 87	FY 88
Written	5	9
Oral	7	7

Please indicate the number of complaints referred to each other governmental agency (federal, state and local) in each fiscal year:

	FY 87	FY 88
Medical Board	6	8
Dental Board	1	2
MN Department of Health	4	5
Orono Police Department	1	0
Drug Enforcement Administration	0	1

Clause o: **Summarize, by specific category, the substance of the complaints and communications referred to in clause (n) of MS 214.07 and, for each specific category, the responses or dispositions thereof pursuant to M.S. 214.10 and 214.11 (indicate authority/citations for disposition).**

SUMMARY OF COMPLAINTS AND COMMUNICATIONS BY SPECIFIC CATEGORY.	SUMMARY OF RESPONSES AND DISPOSITION FOR EACH SPECIFIC CATEGORY
55 Prescription Errors	All complaints investigated, no disciplinary action taken. All pharmacists were subject to educational sessions as per 214.10
49 Unprofessional Conduct	Dismissed (214.10)
5 Pricing issues	Dismissed (214.10)
3 Labeling errors	Dismissed (214.10)
3 Billing errors	Dismissed (214.10)
2 Schemes for obtaining controlled Substances	Dismissed (214.10)
2 No Pharmacist on duty	Dismissed (214.10)
2 Customer Chemical Dependency	Dismissed (214.10)
3 Chemical Dependency	Dismissed (214.10)
1 No case stated	Dismissed (214.10)
1 Scheme for obtaining prescription blanks	Dismissed (214.10)
1 Contaminated Medication	Dismissed (214.10)
1 Advertising	Dismissed (214.10)
1 Advertising	Not in our jurisdiction
1 Discounts	Not in our jurisdiction
1 Stealing from the Pharmacy	Dismissed (214.10)

Item 31. FOR ALL HEALTH RELATED BOARDS EXCEPT THE BOARD OF VETERINARY MEDICINE. PER M.S. 1992 SUPPLEMENT, SECTION 214.10, SUBD. 10(b): PROVIDE A SUMMARY OF EACH INDIVIDUAL CASE (COMPLAINT OR OTHER COMMUNICATION) THAT INVOLVED POSSIBLE SEXUAL CONTACT OF A LICENSEE WITH A PATIENT OR CLIENT.

None.

Clause p: STATE ANY OTHER OBJECTIVE INFORMATION WHICH THE BOARD MEMBERS BELIEVE WILL BE USEFUL IN REVIEWING BOARD ACTIVITIES.

Many warning letters (over 100) were written and several formal disciplinary actions took place as a result of inspections by our staff.

1. An informal but yet effective sharing of information is in effect between the health licensing boards. With all health licensing boards located in the same building communication is continually on-going.

2. Minnesota Board of Pharmacy participates in a national disciplinary clearing house mediated through the National Association of Boards of Pharmacy.

1	Outdated Drugs/Improper use of supportive personnel	Dismissed (214.10)
1	Improper Disposition of legend drugs	Dismissed (214.10)
1	Drugs not disposed of on closing of a pharmacy	Dismissed (214.10)
1	Selling look-alike drugs	Dismissed (214.10)
1	Kickbacks	Dismissed (214.10)